Pharmacological management of South Asians with type 2 diabetes: Consensus recommendations from the South Asian Health Foundation.

Wasim Hanif, Sarah N Ali, Srikanth Bellary, Vinod Patel, Azhar Farooqi, Muhammad Ali Karamat, Mujahid Saeed, Sobha Sivaprasad, Kiran Patel, Kamlesh Khunti

Journal: Diabetic medicine : a journal of the British Diabetic Association 2022;38(4):e14497

PMID: 33301625

Full Text on Ovid Technologies, Inc. View on PubMed

Abstract

South Asians constitute approximately 1.6 billion people from the Indian subcontinent, comprising Afghanistan, Bangladesh, Bhutan, India, Maldives, Nepal, Pakistan and Sri Lanka; and make up the largest diaspora globally. Compared to the White European population, this group is at a higher risk of developing type 2 diabetes along with cardiovascular, renal and eye complications. Over the recent years, a number of new therapies for type 2 diabetes have become available for which cardiovascular outcome trials (CVOTs) have been published. The recent ADA/EASD consensus guidelines on diabetes, pre-diabetes and cardiovascular diseases' offer a transitional shift in type 2 diabetes management. The new consensus recommendations are based on recent CVOTs, many of which had a representation of South Asian cohorts. In light of this new evidence, there is urgent need for an integrated, evidence-based, cost-effective and individualised approach specific for South Asians. This review takes into consideration the evidence from these CVOTs and provides best practice recommendations for optimal management of South Asian people with type 2 diabetes, alongside the previously published consensus report from South Asian Health Foundation in 2014 [1].

Address: Diabetes & Endocrinology, CSL Diabetes, University Hospitals of Birmingham, South Asian Health Foundation, Birmingham, UK.; Diabetes and Endocrinology, Royal Free London NHS Foundation Trust, Diabetes Working Group, South Asian Health Foundation, Birmingham, UK.; School of Life and Health Sciences, Aston University, University Hospitals Birmingham, Birmingham, UK.; Diabetes and Clinical Skills, Warwick Medical School, University of Warwick, Coventry, UK.; South Asian Health Foundation, Birmingham, UK.; East Leicester Medical Practice, Leicester City CCG, BME Centre for Health, ARC East Midlands, Leicester, UK.; Diabetes and Endocrinology, UHB TPD Diabetes and Endocrinology, Health Education, Birmingham, UK.; Queen Elizabeth Hospital Birmingham, University Hospitals Birmingham, University of Birmingham, Birmingham, UK.; NIHR Moorfields Biomedical Research Centre and UCL Institute of Ophthalmology, London, UK.; University Hospitals Coventry & Warwickshire NHS Trust, Warwick Medical School, University of Warwick, Coventry University, Coventry, UK.; Primary Care Diabetes & Vascular Medicine, Diabetes Research Centre and The Centre for Black Minority Health, University of Leicester, Leicester, UK.

DOI: 10.1111/dme.14497

Link outs

Free resources

Medical:

https://medlineplus.gov/diabetestype2.html

Other Literature Sources:

https://scite.ai/reports/33301625

Research Materials:

https://antibodies.cancer.gov/detail/CPTC-ADA-1

Subscription / membership required

Full Text Sources:

MeSH Terms: Afghanistan, Asia, Asian People, Bangladesh, Bhutan, Consensus, Diabetes Mellitus, Type 2, Humans, India, Indian Ocean Islands, Nepal, Pakistan, Practice Guidelines as Topic, Societies, Medical, Sri Lanka